Closed-Loop Study with Tandem “Artificial Pancreas” Showed Promising Results in Children
A 16-week, multi-center, randomized trial of over 100 children aged 6 to 13 at sites around the U.S. showed improved…
Moving the Needle on the High-Risk T1D Patient – Lessons and Perspectives from the T1D Exchange Quality Improvement Collaborative
The T1D Exchange Quality Improvement Collaborative (QIC) is a T1D learning health system that includes over 10 endocrinology centers nationwide, working collaboratively on a shared goal of improving outcomes for people with T1D. The program is coordinated by the QI team at T1D Exchange in Boston.
A Message from Our CEO
We are deeply saddened to observe the recent needless loss of innocent life of George Floyd, and the pain it has inflicted on communities throughout our country. While we have recently been focused on the challenges posed by the global COVID-19 pandemic, including its disproportionate impact on people of color, this recent tragedy has only exacerbated these challenges.
Evidencia en el mundo real: Qué significa y por qué es importante para la diabetes tipo 1
Las personas que viven con diabetes tipo 1 aprenden en muchos aspectos a ser científicos e investigadores de sus propias…
Real World Evidence: What It Means and Why it Matters for Type 1 Diabetes
People living with type 1 diabetes learn, in many ways, to be research scientists and investigators of their own lives. We learn how slices of pizza or a plate of spaghetti affects our blood sugar, and how to mediate those effects with multiple boluses of insulin or a long-lasting dose. We discover precisely how much sugar we need to stay steady during an intense workout session.
In doing so, we begin to learn about the meaning and applications of real-world data and evidence. Modern medical and scientific research takes several different approaches to investigation, from randomized, controlled clinical trials to longitudinal, observational studies that examine how people live with various conditions and therapies in the real world.
Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
Tandem CCO Brian Hansen Discusses FDA Approval for Control IQ Algorithm with t:slim X2
Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.